X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.pharmaceutical-technology.com/news/nmpa-zai-labs-repotrectinib/
https://www.onclive.com/view/repotrectinib-gets-breakthrough-therapy-designation-in-china-for-ntrk-tki-pretreated-solid-tumors
https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-announces-nda-acceptance-repotrectinib-patients-ros1
https://news.bms.com/news/details/2023/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Application-for-Repotrectinib-for-the-Treatment-of-Patients-with-Locally-Advanced-or-Metastatic-ROS1-Positive-Non-Small-Cell-Lung-Cancer/default.aspx
https://www.globenewswire.com/news-release/2022/07/27/2487265/0/en/Turning-Point-Therapeutics-Provides-Regulatory-Update-for-Repotrectinib-for-the-Treatment-of-ROS1-Advanced-NSCLC.html
https://www.globenewswire.com/news-release/2022/05/10/2439752/0/en/Turning-Point-Therapeutics-Granted-Breakthrough-Therapy-Designation-for-Repotrectinib-Treatment-in-Patients-With-One-Prior-ROS1-Tyrosine-Kinase-Inhibitor-and-no-Prior-Chemotherapy.html
https://www.globenewswire.com/news-release/2022/04/12/2421462/0/en/Turning-Point-Therapeutics-Announces-Positive-Topline-Data-by-Blinded-Independent-Central-Review-for-Repotrectinib-Across-All-ROS1-Positive-NSCLC-Cohorts-of-Phase-1-2-TRIDENT-1-Stu.html
https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-announces-breakthrough-therapy-designation-granted-0
https://www.globenewswire.com/news-release/2021/10/04/2307947/0/en/Turning-Point-Therapeutics-Granted-Breakthrough-Therapy-Designation-for-Repotrectinib-Treatment-in-Patients-with-NTRK-Positive-TKI-Pretreated-Advanced-Solid-Tumors.html
https://www.globenewswire.com/news-release/2021/10/04/2307947/0/en/Turning-Point-Therapeutics-Granted-Breakthrough-Therapy-Designation-for-Repotrectinib-Treatment-in-Patients-with-NTRK-Positive-TKI-Pretreated-Advanced-Solid-Tumors.html
https://www.globenewswire.com/news-release/2021/08/16/2281187/0/en/Turning-Point-Therapeutics-Initiates-TRIDENT-2-Clinical-Study-Investigating-Repotrectinib-Trametinib-Combination-in-KRAS-G12D-Mutated-Advanced-Solid-Tumors.html
https://www.globenewswire.com/news-release/2021/01/29/2166608/0/en/Turning-Point-Therapeutics-Reports-Updated-Interim-Data-From-Registrational-Phase-2-Trident-1-Study-of-Repotrectinib-in-Patients-With-ROS1-Positive-TKI-Na%C3%AFve-Non-Small-Cell-Lung-Ca.html
https://www.globenewswire.com/news-release/2020/12/08/2141343/0/en/Turning-Point-Therapeutics-Granted-FDA-Breakthrough-Therapy-Designation-for-Repotrectinib-Treatment-in-Patients-with-ROS1-Positive-Metastatic-Non-Small-Cell-Lung-Cancer-Who-Have-No.html
https://www.globenewswire.com/news-release/2020/10/21/2111802/0/en/Turning-Point-Therapeutics-Announces-Abstract-For-TRIDENT-1-Clinical-Study-of-Repotrectinib-Accepted-For-Presentation-at-World-Conference-on-Lung-Cancer.html
https://ir.tptherapeutics.com/news-releases/news-release-details/turning-point-therapeutics-reports-early-interim-data
https://endpts.com/turning-point-touts-positive-pivotal-nsclc-data-hints-at-even-faster-ok-but-can-it-beat-pfizer-and-roche/
http://www.globenewswire.com/news-release/2020/04/16/2017380/0/en/Clinical-Cancer-Research-Highlights-Potent-Antitumor-Activity-of-Repotrectinib-in-Treatment-Na%C3%AFve-and-Solvent-Front-Mutation-Ros1-Positive-Non-Small-Cell-Lung-Cancer.html
Market Place
Share 
